SIGA Technologies' Earnings Call: RFP Delay Reasons and International Order Claims Don’t Match

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $38 million in product-related revenues for Q2 2026, mostly IV TPOX ($24M) and international sales ($13M). Q1 had minimal product revenues.
• EPS: $0.17 per diluted share for Q2 2026. Six months ended June 30, 2026: $0.13 per diluted share.

Business Commentary:

Revenue Performance and Product Deliveries:

• SIGA reported product-related revenues of $38 million for the second quarter of 2026, with $24 million from IV TPOX deliveries to the U.S. Strategic National Stockpile and $13 million from international sales.
• This revenue performance demonstrates the company's ability to generate income through diverse product deliveries and government contracts, despite quarter-to-quarter variability.

U.S. Government Contract and Preparedness Efforts:

• The $24 million in IV TPOX deliveries marks the fulfillment of the final product order under the 19C contract, highlighting a long-standing partnership with the U.S. government since 2018.
• Despite slower progress in securing a new multi-year procurement contract, ongoing funding and recent deliveries affirm the significance of TPOX in U.S. smallpox preparedness strategies.

International Business Expansion:

• SIGA received a $13 million order from a country in the Asia-Pacific region and delivered oral TPOX courses to a European customer, showcasing the company's international reach.
• The recent exclusive license and distribution agreement with HICMA MENA FCE aims to expand TPOX's footprint across the Middle East and North Africa, leveraging regional expertise for broader market access.

Pipeline and Development Programs:

• The company is advancing its post-exposure prophylaxis (PEP) and pediatric programs, targeting an FDA submission in the first half of 2027 and expecting phase one study results by year-end.
• These developments are critical for extending TPOX coverage across all population segments, including children, who are particularly vulnerable in a smallpox outbreak.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed confidence in TPOX's role in preparedness and highlighted strong deliveries: 'I am pleased to report that SIGA continues to make product deliveries and generate revenues... The threat of smallpox is real, and preparedness requires proactive, sustained government investment... As 2026 progresses, we believe the case for preparedness has never been clearer.'

Q&A:

• Question from Jyoti Prakash (Edison Group): Now, the process has been slower than expected. What do you believe is the reason for this delay? And do you still think that an award in the second half of the year is possible? And will that be timely enough to support TPOX deliveries in 2027?
  Response: The delay is due to the scale of change within HHS, new initiatives, evolving priorities, contract transition from BARDA to S&S, and key open leadership positions. Despite the delay, they remain confident in TPOX's role in U.S. preparedness.

• Question from Jyoti Prakash (Edison Group): Since the RFP has been delayed and there is some uncertainty on the timing, are you placing greater strategic emphasis on international markets?
  Response: They are targeting a new international contract and an order with delivery expected by March 2027, indicating increased strategic emphasis on international markets.

• Question from Jyoti Prakash (Edison Group): Your promotion agreement with Meridian recently expired. Has it been renewed or replaced?
  Response: Nothing has changed operationally; SIGA has handled all international functions since 2024, and the international business continues without interruption.

Contradiction Point 1

Reason for U.S. RFP Delay

Different primary factors cited for the same delay.

Jyoti Prakash (Edison Group) - Jyoti Prakash (Edison Group)

2026Q2: Factors contributing to the delay include the scale of change within HHS (new initiatives, evolving priorities, transition of the contract from BARDA to the Strategic National Stockpile), and key open leadership positions. - Dan Luxhire(CFO)

What is the reason for the slower-than-expected U.S. RFP process, and does the company still anticipate an award by the second half of the year that would be timely enough to support TPOX deliveries in 2027? - Jyoti Prakash (Edison Group)

2026Q2: The process is unique and has taken longer than expected due to factors like scale of change within HHS, new initiatives, evolving priorities, transition of the contract from BARDA to SNS, and key open leadership positions. - Zem Wind(CEO)

Contradiction Point 2

Strategic Emphasis on International Markets

Shift in tone regarding strategic focus on international markets.

Jyoti Prakash (Edison Group) - Jyoti Prakash (Edison Group)

2026Q2: SIGA always focuses on all customers, both domestic and international. The geopolitical environment has prompted many governments to sharpen their focus on biodefense and medical preparedness. - Dan Luxhire(CFO)

Given the delay in the U.S. RFP and uncertainty around timing, is SIGA placing greater strategic emphasis on international markets, and do you expect additional international orders this year? - Jyoti Prakash (Edison Group)

2026Q2: SIGA always focuses on both domestic and international customers. The geopolitical environment has prompted many governments to sharpen their focus on biodefense and preparedness. - Zem Wind(CEO)

Contradiction Point 3

Specificity and Expected Timeline for International Orders

Contradiction on the specificity and confirmed status of international orders.

Jyoti Prakash (Edison Group) - Jyoti Prakash (Edison Group)

2026Q2: SIGA always focuses on all customers... discussions with an international customer are progressing. The company is targeting a new contract and an order against it, with a hoped-for delivery by March of next year. - Dan Luxhire(CFO)

Given the delay in the U.S. RFP and uncertainty around timing, is SIGA shifting strategic emphasis to international markets and expecting additional international orders this year? - Jyoti (Edison Group)

2026Q1: SIGA expects to deliver approximately $13 million of oral TPOXX to an international customer in Q2 and remains actively engaged with other potential customers globally. - Diem Nguyen(CEO)

Contradiction Point 4

Ability to Provide Specific Timing Details for the Next U.S. RFP

Contradiction on the ability to provide specific timing details for the next U.S. RFP.

Jyoti Prakash (Edison Group) - Jyoti Prakash (Edison Group)

2026Q2: Factors contributing to the delay... Despite the delay, SIGA remains confident... - Dan Luxhire(CFO)

What is causing the slower-than-expected U.S. RFP process, and does the company still anticipate an award by year-end that would sufficiently support TPOX deliveries in 2027? - Jyoti Prakash (Edison Investment Research Limited)

2025Q4: No specific timing details on the next RFP can be shared today. However, ongoing productive conversations confirm that preparedness is a focus area... - Diem Nguyen(CEO)

Contradiction Point 5

Certainty of Additional International Orders in 2026

Contradiction on the specificity and certainty of expectations for additional international orders.

Jyoti Prakash (Edison Group) - Jyoti Prakash (Edison Group)

2026Q2: While international procurement decisions are complex and specific outcomes cannot be commented on, discussions with an international customer are progressing. The company is targeting a new contract and an order against it, with a hoped-for delivery by March of next year. - Dan Luxhire(CFO)

Amid the delay in the U.S. RFP, is SIGA shifting strategic focus to international markets and expecting additional international orders this year? - Jyoti Prakash (Edison Investment Research Limited)

2025Q4: Additional international sales may occur in 2026, but processes are complex and time-consuming; the company remains actively engaged with a range of international customers and will announce developments when appropriate. - Daniel Luckshire(CFO)